Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study

BACKGROUND: Recent studies indicate the benefit of treatment with osimertinib over that with conventional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for untreated EGFR-mutated non-small cell lung cancer (NSCLC). Cobas ver2 is the only companion diagnostic method for det...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogo, Mariko, Fujimoto, Daichi, Hosoya, Kazutaka, Nagata, Kazuma, Nakagawa, Atsushi, Tachikawa, Ryo, Yamashita, Daisuke, Kitamura, Yuka, Imai, Yukihiro, Tomii, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006383/
https://www.ncbi.nlm.nih.gov/pubmed/32028905
http://dx.doi.org/10.1186/s12885-020-6603-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006383/
https://www.ncbi.nlm.nih.gov/pubmed/32028905
http://dx.doi.org/10.1186/s12885-020-6603-3

Ejemplares similares